Article ID Journal Published Year Pages File Type
8794933 Ophthalmology Retina 2017 7 Pages PDF
Abstract
In nonnaïve patients with active exudative AMD, treatment with a fixed intravitreal aflibercept dosing regimen for 24 months demonstrated sustained improvements in anatomy and vision in patients transitioned from other anti-vascular endothelial growth factor agents and stability when compared with 12-month outcomes. Patients who benefited most were those with worse vision at entry and longer duration of disease.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
, , , , , , ,